Abstract
Introduction: Tildrakizumab, an anti-IL-23p19 monoclonal antibody approved for the treatment of plaque psoriasis, is effective and safe for up to 3 years.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
